Greenwich LifeSciences Inc. (GLSI): Price and Financial Metrics


Greenwich LifeSciences Inc. (GLSI): $38.96

-0.48 (-1.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GLSI Stock Price Chart Interactive Chart >

Price chart for GLSI

GLSI Price/Volume Stats

Current price $38.96 52-week high $158.07
Prev. close $39.44 52-week low $3.26
Day low $38.65 Volume 93,500
Day high $40.40 Avg. volume 459,246
50-day MA $36.90 Dividend yield N/A
200-day MA $0.00 Market Cap 502.58M

Greenwich LifeSciences Inc. (GLSI) Company Bio


Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.


GLSI Latest News Stream


Event/Time News Detail
Loading, please wait...

GLSI Latest Social Stream


Loading social stream, please wait...

View Full GLSI Social Stream

Latest GLSI News From Around the Web

Below are the latest news stories about Greenwich LifeSciences Inc that investors may wish to consider to help them evaluate GLSI as an investment opportunity.

Greenwich LifeSciences Set to Join Russell 2000® Index

Greenwich LifeSciences Set to Join Russell 2000® Index

Yahoo | June 8, 2021

Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer Recurrence

Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have previously undergone surgery. Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting. Final safety conclusions are that GP2 immunotherapy is well tolerated and that no serious adverse events related to GP2 immunotherapy were reported over the full five-year follow-up period. Data shows 100% disease-free surviv

Yahoo | June 7, 2021

Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated

Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming GP2 Treatment is Well Tolerated

Yahoo | June 7, 2021

1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?

The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?

Yahoo | April 21, 2021

Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Thursday Morning

It's Thursday morning and investors keeping track of the pre-market will want to make sure they check out this list of movers!

William White on InvestorPlace | April 15, 2021

Read More 'GLSI' Stories Here

GLSI Price Returns

1-mo 18.24%
3-mo 36.22%
6-mo -26.35%
1-year N/A
3-year N/A
5-year N/A
YTD 6.83%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7443 seconds.